TELA Bio Inc (NAS:TELA)

Q3 2025 TELA Bio Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $1.11 (-2.63%)

Transcript 10-Q8-K

Key Points

Positve

TELA Bio Inc (TELA) reported a revenue of $20.7 million for Q3 2025, marking a 9% growth over the prior year.
The company achieved a significant milestone with over 100,000 implantations of Ovitex and Ovitex PRS globally.
Sales and marketing expenses decreased from $16.5 million in the prior year to $15.2 million in Q3 2025, indicating improved financial prudence.
TELA Bio Inc (TELA) strengthened its balance sheet by refinancing and upsizing its debt facility and completing a $13 million equity offering.
The company expanded its market presence, securing NHS finance sign-off in the UK and broadening market access in the US by an additional 835 hospitals.

Negative

Q3 results were lower than expected, despite achieving a new global quarterly revenue record.
The company reported a net loss of $8.6 million in Q3 2025, compared to $10.4 million in the prior year period.
Gross margin remained flat at 68% for both Q3 2025 and Q3 2024, indicating no improvement in profitability.
There was a decrease in Ovitex PRS unit sales growth, which was only 3% for the quarter.
The company had to revise its 2025 revenue guidance and provided a conservative growth expectation of 15% for 2026.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TELA.OQ - TELA Bio Inc
Q3 2025 TELA Bio Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to Otello Bio 3rd quarter 2025 earnest conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the prepared remarks. As a reminder, this conference call is being recorded. I would now like to turn the conference call over to Louisa Smith of the Martin Group. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Kelvin, and good afternoon, everyone. Earlier today, Telebio released financial results for the 3rd quarter, 2025. A copy of the press release is available on

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.